Biotech capital raised via IPO has increased dramatically over the past couple of years. The Q2 2019 initial public offerings (IPOs) market has heated up after a Q1 2019 slowdown partially driven by the longest government shutdown in U.S. history. Ernst and Young reported that 205 IPOs were executed in 2018 on the New York Stock Exchange (NYSE) and Nasdaq, raising almost $53 billion of capital. The biotechnology sector was represented well: Click Here For Complete Article Text
|
||||||||||||||||||
| Application Sequencing | ||||||||||||||||||
|
||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | |||||||||
|
|
|
|
|
|
|
||||||||||||